Emerging Infections and Parasitology Laboratory, NCSD, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, 1212, Bangladesh.
Virology Laboratory, IDD, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, 1212, Bangladesh.
Int J Infect Dis. 2022 Jan;114:105-111. doi: 10.1016/j.ijid.2021.11.007. Epub 2021 Nov 7.
The democratization of diagnostics is one of the key challenges towards containing the transmission of coronavirus disease 2019 (COVID-19) around the globe. The operational complexities of existing PCR-based methods, including sample transfer to advanced central laboratories with expensive equipment, limit their use in resource-limited settings. However, with the advent of isothermal technologies, the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is possible at decentralized facilities.
In this study, two recombinase-based isothermal techniques, reverse transcription recombinase polymerase amplification (RT-RPA) and reverse transcription recombinase-aided amplification (RT-RAA), were evaluated for the detection of SARS-CoV-2 in clinical samples. A total of 76 real-time reverse transcription PCR (real-time RT-PCR) confirmed COVID-19 cases and 100 negative controls were evaluated to determine the diagnostic performance of the isothermal methods.
This investigation revealed equally promising diagnostic accuracy of the two methods, with a sensitivity of 76.32% (95% confidence interval 65.18-85.32%) when the target genes were RdRP and ORF1ab for RT-RPA and RT-RAA, respectively; the combination of N and RdRP in RT-RPA augmented the accuracy of the assay at a sensitivity of 85.53% (95% confidence interval 75.58-92.55%). Furthermore, high specificity was observed for each of the methods, ranging from 94.00% to 98.00% (95% confidence interval 87.40-9.76%).
Considering the diagnostic accuracies, both RT-RPA and RT-RAA appear to be suitable assays for point-of-need deployment for the detection of the pathogen, understanding its epidemiology, case management, and curbing transmission.
诊断技术的民主化是控制全球 2019 年冠状病毒病(COVID-19)传播的关键挑战之一。现有的基于聚合酶链反应(PCR)的方法存在操作复杂的问题,包括将样本转移到具有昂贵设备的高级中心实验室,这限制了它们在资源有限的环境中的使用。然而,随着等温技术的出现,有可能在分散的设施中检测到严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)。
在这项研究中,评估了两种基于重组酶的等温技术,逆转录重组酶聚合酶扩增(RT-RPA)和逆转录重组酶辅助扩增(RT-RAA),用于检测临床样本中的 SARS-CoV-2。评估了总共 76 例实时逆转录 PCR(实时 RT-PCR)确诊的 COVID-19 病例和 100 例阴性对照,以确定等温方法的诊断性能。
这项研究表明,这两种方法具有同样有前途的诊断准确性,当 RT-RPA 和 RT-RAA 的靶基因分别为 RdRP 和 ORF1ab 时,其灵敏度分别为 76.32%(95%置信区间 65.18-85.32%);当 RT-RPA 中 N 和 RdRP 联合使用时,检测的灵敏度提高到 85.53%(95%置信区间 75.58-92.55%)。此外,每种方法的特异性都很高,范围从 94.00%到 98.00%(95%置信区间 87.40%-9.76%)。
考虑到诊断准确性,RT-RPA 和 RT-RAA 似乎都是适合用于现场检测病原体、了解其流行病学、病例管理和遏制传播的检测方法。